A subscription to JoVE is required to view this content. Sign in or start your free trial.
Transcatheter aortic valve implantation (TAVI) has been shown to generate the best clinical outcomes when performed by the percutaneous transfemoral approach. Intravascular lithotripsy (IVL) can facilitate a transfemoral process in patients with calcified iliofemoral vascular disease and borderline intraluminal diameters. The present protocol describes IVL-assisted transfemoral TAVI.
During the last decade, transcatheter aortic valve implantation (TAVI) has evolved as a well-established therapy for aging patients suffering from symptomatic severe aortic valve stenosis. This is also reflected in the recently updated international guidelines on managing patients with valvular heart disease. A transfemoral (TF) TAVI approach has proven superior to alternative access strategies. With the introduction of intravascular lithotripsy (IVL), patients with calcified iliofemoral vascular disease and borderline intraluminal diameters have also become candidates for percutaneous TF-TAVI. Moreover, IVL reduces the risk of major vascular complications by modifying the superficial and deep vascular calcium, thereby changing the vessel compliance and controlling luminal expansion. In this way, IVL has shown to safely facilitate TF delivery of TAVI devices in patients with calcified peripheral artery disease. The present article aims to provide a detailed step-by-step description on how to perform IVL-assisted TF-TAVI safely and efficiently. Furthermore, a literature review on the outcomes obtained with this technology is included, along with a concise discussion on this unique TAVI approach.
Transcatheter aortic valve implantation (TAVI) has proven to be a valuable therapy for elderly patients suffering from symptomatic severe aortic valve stenosis (AS) across all surgical risk categories1,2. The data and outcomes are most convincing for those patients in whom the TAVI procedure can be performed by transfemoral (TF) approach. TAVI by alternative access, such as transsubclavian, transaxillary, transcarotid, transcaval, and transapical access, can also be considered. However, the complication rates reported for TAVI by alternative access are higher than TF-TAVI3,
The protocol is approved by the human research ethics committee of Copenhagen University Hospital, and the studies are conducted following the guidelines of the said ethics committee. Following local policies, all patients gave informed consent for the TAVI procedure, cardiac CT scanning, and anonymous data for research.
1. Preprocedural planning
IVL treatment (Figure 1) of calcified PAD was first investigated in the DISRUPT-PAD European pre-market study18. The study showed an acute increase in vessel diameter in 35 patients following peripheral IVL treatment at the cost of only minimal vessel injury. The multi-center DISRUPT-PAD II trial19 confirmed these findings in 60 patients. DISRUPT PAD III20 was designed as a real-world, prospective, multi-center study in .......
Since the introduction of TAVI as a treatment option for patients with severe symptomatic AS, studies and registries have demonstrated that TAVI by TF approach generates better procedural success and lower complication rates3,4,23. As a result, most centers nowadays seek to perform most of their TAVI procedures by percutaneous TF approach23.
The introduction of IVL as a new too.......
The authors have none to acknowledge.
....Name | Company | Catalog Number | Comments |
0.014” guidewire | Floppy II Extra Support Guide Wire, Abbott, USA | 22299M | |
0.035’’ stiff guidewire | Amplatz superstiff j-tip 7 cm floppy, Boston Scientific, USA | M001465020 | |
20 mL syringe | |||
6 F or 8 F femoral sheat | Radifocus Introducer II, Terumo | RS*B70N10MRD and RS*B80N10MRD | |
6-8 F Arrow sheat 35 cm- if contralateral access | Teleflex | CL07635 and CL07835 | |
Arterial puncture needle | Percutaneous entry thinwall needle, Cook Medical | SDN18-18-7.0 | |
Contrast solution | Visipaque 350, GE Healthcare | ||
CT angiography-based 3D reconstruction dedicated software | 3mensio, Pie Medical, The Netherlands | ||
Diagnostic catheter | 6F IMA diagnostic catheter, Cordis | 534-6605 | |
Echo probe sterile cover | CIV-flex transducer cover, CIVCO | 610-1212 | |
Indeflator device (20 mL) | Everest 30, Medtronic | AC3200 | |
IVL Connector Cable | Shockwave medical | IVLCC | |
IVL generator | Shockwave medical | IVLGCC | |
Local anesthetic | Xylocain 10 mg/mL, Aspen | ||
Non-compliant balloon | Z-MED II balloon 6 to 8 mm, Numed Canada inc. | PDZ622 | |
Safety wire | 0.018’’ Platinum Plus guidewire, Boston Scientific, USA | M0014666050 | |
Shockwave M5/M5+ catheter (7 mm-8 mm diameter) | Shockwave medical | M5IVL7060 - M5PIVL7060 - M5PIVL8060 | |
Standard J-wire | angiodyn guide wire j-tip, B. Braun | 5050200 | |
Sterile cover for shockwave connector cable | camera drape, Mönlycke health care | ||
Three-way stopcock | |||
Unfractionated heparin | 10 mL vials of 1000 IE/mL, Amgros I/S | ||
Vascular closure device | Perclose Prostyle device, Abbott, USA | 12773-02 | |
Vascular echo probe | |||
Manta VCD, Essential Medical, USA | 2156NE, 2115NE |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved